# Control of COVID-19 Outbreaks in Long Term Care

> **NCT04448119** · PHASE2 · TERMINATED · sponsor: **Appili Therapeutics Inc.** · enrollment: 67 (actual)

## Conditions studied

- COVID-19
- SARS-CoV-2

## Interventions

- **DRUG:** Favipiravir
- **DRUG:** Favipiravir Placebo

## Key facts

- **NCT ID:** NCT04448119
- **Lead sponsor:** Appili Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-16
- **Primary completion:** 2021-10-30
- **Final completion:** 2021-10-30
- **Target enrollment:** 67 (ACTUAL)
- **Why stopped:** Recruitment challenges
- **Last updated:** 2023-02-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04448119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04448119, "Control of COVID-19 Outbreaks in Long Term Care". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04448119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*